Powerful clinical efficacy across patient groups

 

In 1st line with letrozole
In an updated non-prespecified PFS analysis of PALOMA-2, 1st line IBRANCE® + letrozole demonstrated PFS improvements vs placebo + letrozole in patients with visceral metastases, including lung and liver*†2

  • In PALOMA-2, 48.2% of patients treated with IBRANCE® + letrozole had visceral disease, which included lung and liver2

Visceral disease

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Rugo H, et al. 2019.2
Data cut-off date: May 31, 2017.
*Evaluated according to RECIST Version 1.1.3† Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE® + letrozole arm.2

In 1st or later line with fulvestrant
In PALOMA-3, IBRANCE® + fulvestrant in 1st line or later demonstrated PFS improvements vs placebo + fulvestrant in patients with visceral metastases, including lung and liver*4

  • In PALOMA-3, 58% of patients treated with IBRANCE® + fulvestrant had visceral disease, which included lung and liver†4
clinical-efficacy-across-patient-groups
 

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Turner NC, et al. 2018.4
Data cut-off date: 23 October, 2015.
*Evaluated according to RECIST Version 1.1.5† Visceral disease included liver, lung, pleura, peritoneum, and/or brain metastases.5

CI = confidence interval; FUL = fulvestrant; HR = hazard ratio; LET = letrozole; = number of patients; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.

    References
    1. IBRANCE® Summary of Product Characteristics.
    2. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
    3. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
    4. Turner NC, et al. Ann Oncol. 2018;29(3):669-680.
    5. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.

    ©2020 Pfizer. All rights reserved. PP-IBR-IRL-0501 Date of Preparation: March 2022 Legal Category: S1A